LOADING
Comparing Johnson & Johnson (JNJ) and AbbVie Inc (ABBV), both in the Health Care sector. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JNJ | ABBV |
|---|---|---|
| Price | $272.63 | $264.68 |
| Change Today | +0.88% | -0.11% |
| Market Cap | $651.3B | $468.2B |
| P/E Ratio | 31.4 | 74.6 |
| Forward P/E | 23.2 | 18.9 |
| PEG Ratio | 4.73 | 0.43 |
| EPS | $8.62 | $3.55 |
| Revenue Growth (YoY) | 6.6% | 10.2% |
| Profit Margin | 21.5% | 9.8% |
| Return on Equity | 25.7% | 62.3% |
| Dividend Yield | 1.96% | 2.61% |
| Beta | 0.23 | 0.28 |
| 52-Week High | $276.47 | $267.47 |
| 52-Week Low | $170.33 | $189.40 |
| Volume | 93K | 49K |
Johnson & Johnson is the larger company by market capitalization. Johnson & Johnson trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. AbbVie Inc offers a higher dividend yield for income investors. Johnson & Johnson has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.